See more : Eco-Tek Group, Inc. (ETEK) Income Statement Analysis – Financial Results
Complete financial analysis of TuHURA Biosciences, Inc. (HURA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of TuHURA Biosciences, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- PROEN Corp Public Company Limited (PROEN.BK) Income Statement Analysis – Financial Results
- Trilogy Metals Inc. (TMQ) Income Statement Analysis – Financial Results
- BELLSYSTEM24 Holdings, Inc. (6183.T) Income Statement Analysis – Financial Results
- Schibsted ASA (SBSNF) Income Statement Analysis – Financial Results
- Baroque Japan Limited (3548.T) Income Statement Analysis – Financial Results
TuHURA Biosciences, Inc. (HURA)
About TuHURA Biosciences, Inc.
TuHURA Biosciences, Inc. is a phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company is headquartered in Tampa, FL.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 32.00K | 10.00K | 16.35K | 24.53K | 16.68K | 10.29K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | -32.00K | -10.00K | -16.35K | -24.53K | -16.68K | -10.29K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 9.40M | 7.93M | 4.88M | 11.82M | 3.63M | 3.66M | 7.13M | 5.00M | 3.36M | 2.56M | 2.34M | 0.00 | 0.00 | 0.00 |
| General & Administrative | 4.14M | 2.01M | 2.38M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 4.14M | 2.01M | 2.38M | 9.73M | 4.50M | 4.72M | 4.02M | 3.30M | 2.84M | 2.17M | 3.95M | 18.89K | 33.14K | 5.58K |
| Other Expenses | 16.22M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 29.76M | 9.93M | 7.25M | 21.54M | 8.13M | 8.38M | 11.15M | 8.30M | 6.20M | 4.72M | 6.29M | 18.89K | 33.14K | 5.58K |
| Cost & Expenses | 29.76M | 9.93M | 7.25M | -21.57M | -8.14M | -8.40M | -11.17M | -8.32M | -6.21M | -4.72M | -6.29M | -18.89K | -33.14K | -5.58K |
| Interest Income | 89.67K | 57.35K | 0.00 | 0.00 | 75.00K | 60.70K | 33.24K | 457.00 | 108.00 | 363.00 | 2.49K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 18.69K | 0.00 | 629.29K | 120.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.09K | 8.02K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 177.38K | 373.09K | 380.69K | 32.00K | 10.00K | 16.35K | 24.53K | 16.68K | 10.29K | 378.97K | -1.99M | 0.00 | 0.00 | 0.00 |
| EBITDA | -29.12M | -9.56M | -6.01M | -38.15M | -9.12M | -8.03M | -11.11M | -8.07M | -8.85M | -4.35M | -8.28M | -18.89K | -33.14K | -5.58K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -29.76M | -9.93M | -7.25M | -21.57M | -8.14M | -8.40M | -11.17M | -8.32M | -6.21M | -4.72M | -6.29M | -18.89K | -33.14K | -5.58K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 447.89K | 566.34K | 238.47K | -16.73M | -982.00K | 350.28K | 36.35K | 239.07K | -2.65M | 376.89K | -2.00M | 0.00 | 0.00 | 0.00 |
| Income Before Tax | -29.32M | -9.37M | -7.02M | -38.30M | -9.13M | -8.05M | -11.14M | -8.08M | -8.86M | -4.35M | -8.29M | -18.89K | -33.14K | -5.58K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -1.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | -29.32M | -9.37M | -7.02M | -38.30M | -9.13M | -8.05M | -11.14M | -8.08M | -8.86M | -4.35M | -8.29M | -18.89K | -33.14K | -5.58K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.12 | -202.39 | -0.17 | -2.81K | -1.53K | -5.52K | -9.49K | -12.89K | -14.55K | -7.99K | -19.56K | -124.36 | -115.00 | -46.30 |
| EPS Diluted | -0.12 | -202.39 | -0.17 | -2.81K | -1.53K | -5.52K | -9.49K | -12.89K | -14.55K | -7.99K | -19.56K | -124.36 | -115.00 | -46.30 |
| Weighted Avg Shares Out | 68.01M | 46.29K | 42.03M | 14.79K | 5.97K | 1.47K | 1.19K | 688.40 | 625.63 | 543.82 | 423.82 | 151.85 | 288.14 | 120.56 |
| Weighted Avg Shares Out (Dil) | 68.01M | 46.29K | 42.03M | 14.79K | 5.97K | 1.47K | 1.19K | 688.40 | 625.63 | 543.82 | 423.82 | 151.85 | 288.14 | 120.56 |
TuHURA Biosciences, Inc. (Nasdaq: HURA) Outlines Development Pathway for Single Phase 3 Accelerated Approval Registration Trial in First Line Treatment of Advanced or Metastatic Merkel Cell Carcinoma and Provides Business Update
IFx-2.0, a first-in-class innate immune response agonist, entering single Phase 3 accelerated approval registration trial in first half of 2025 for first line treatment of Merkel Cell Carcinoma (MCC) under Special Protocol Assessment (SPA) agreement with U.S. Food and Drug...
TuHURA Biosciences (Nasdaq: HURA) Announces Webcast Replay of Panel Presentation at the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC
TAMPA, FL / ACCESSWIRE / October 23, 2024 / TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 registration-stage immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, today announced that TuHURA recently participated at the...
TuHURA Biosciences (NASDAQ:HURA) to Present at the Virtual Investor "New to the Street" Event
Live moderated webcast with Dr. Jim Bianco, President and Chief Executive Officer of TuHURA on Wednesday, October 30th at 4 PM ET TAMPA, FL / ACCESSWIRE / October 22, 2024 / TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a...
Source: https://incomestatements.info
Category: Stock Reports